


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of formula I



(I),

in which

- A stands for phenylene or thiophenylene,
 B stands for a bond or for C_1 - C_{12} -alkylene, C_2 - C_{12} -alkenylene, C_2 - C_{12} -alkynylene, C_3 - C_8 -cycloalkylene, or phenylene that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, cyano, nitro, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_{10} -cycloalkyl, C_1 - C_6 -hydroxyalkyl, $-(CH_2)_pSO_3R^8$, or with the group $-NR^8R^9$, $-NR^8COR^9$, $-NR^8CSR^9$, $-NR^8SOR^9$, $-NR^8SO_2R^9$, $-NR^8CONR^8R^9$, $-NR^8COOR^9$, $-NR^8C(NH)NR^9R^{10}$, $-NR^8CSNR^9R^{10}$, $-NR^8SONR^9R^{10}$, $-NR^8SO_2NR^9R^{10}$, $-COR^8$, $-CSR^8$, $-S(O)R^8$, $-S(O)_2R^8$, $-S(O)_2NR^8R^9$, $-SO_3R^8$, $-CO_2R^8$, $-CONR^8R^9$, $-CSNR^8R^9$, $-SR^8$ or $-CR^8(OH)-R^9$,

X and Y, in each case independently of one another, stand for oxygen, sulfur or for the group $-NR^{11}$ -, $-NR^{11}(CH_2)$ -, $-NR^{11}O$ -, $-ONR^{11}$ -, $=CR^6R^7$, $=C=O$, $=C=S$, $=SO$, $=SO_2$, $-C(O)O$ -, $-OC(O)$ -, $-S(O)O$ -, $-OS(O)$ -, $-S(O)_2O$ -,

-OS(O)₂-, -CONR⁸-, -N(COR⁸)-, -N(COOR⁸)-, -N(CONR⁸R⁹)-, -NR⁸CO-,
 -OCONR⁸-, -NR⁸C(O)O-, -CSNR⁸-, -NR⁸CS-, -OCSNR⁸-, -NR⁸CSO-,
 -SONR⁸-, -NR⁸SO-, -SO₂NR⁸-, -S(O)₂N(COR⁸)-, -NR⁸SO₂-,
 -NR⁸CONR⁹-, -NR⁸CSNR⁹-, -NR⁸SONR⁹-, -NR⁸SO₂NR⁹-,
 -NR⁸C(O)NR⁹- or -NR⁸C(S)NR⁹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen,

hydroxy, halogen, nitro, cyano, C₁-C₆-alkyl, C₂-C₆- alkenyl, C₂-C₆-alkinyl, C₃-
 C₁₀-cycloalkyl, the group -C₁-C₆-alkyloxy-C₁-C₆-alkyloxy, -(CH₂)_pPO₃(R¹⁰)₂,
 -NR⁸R⁹, -NR⁸COR⁹, -NR⁸CSR⁹,
 -NR⁸SOR⁹, -NR⁸SO₂R⁹, -NR⁸CONR⁹R¹⁰, -NR⁸COOR⁹,
 -NR⁸C(NH)NR⁹R¹⁰, -NR⁸CSNR⁹R¹⁰, -NR⁸SONR⁹R¹⁰, -NR⁸SO₂NR⁹R¹⁰, -
 COR⁸-, -CSR⁸-, -S(O)R⁸-, -S(O)(NH)R⁸-, -S(O)₂R⁸-, -S(O)₂NR⁸R⁹-, -S(O)₂N=CH-
 NR⁸R⁹,
 -SO₃R⁸-, -CO₂H, -CO₂R⁸-, -CONR⁸R⁹-, -CSNR⁸R⁹-,
 -SR⁸ or -CR⁸(OH)-R⁹, or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl,
 or C₃-C₁₀-cycloalkyl, that is substituted in one or more places in the same way
 or differently with hydroxy, C₁-C₆-alkoxy, halogen, phenyl or with the group -
 NR³R⁴, and the phenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, and
 -(CH₂)_p-C₃-C₁₈-heteroaryl itself optionally can be substituted in one or more
 places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₁-
 C₆-alkoxy, or with the group -CF₃ or -OCF₃;

R² stands for hydrogen or C₁-C₁₀-alkyl,

R³ stands for hydrogen, halogen, nitro, cyano, C₁-C₁₀-alkyl, halo-C₁-C₁₀-
 alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, hydroxy, C₁-C₆-
 alkoxy, C₁-C₆-alkylthio, amino, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl, C₁-C₆-
 hydroxyalkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-
 alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl),
 C₁-C₆-alkanoyl,
 -CONR⁸R⁹-, -COR¹⁰-, C₁-C₆-alkyloAc, carboxy, or for the group -NR⁸R⁹,
 or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, or C₃-C₁₀-cycloalkyl,
 that is substituted in one or more places in the same way or differently with

hydroxy, halogen, C₁-C₆-alkoxy,
 C₁-C₆-alkylthio, amino, cyano, C₁-C₆-alkyl, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl,
 C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₁-C₆-
 alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl,
 -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -
 CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkyLOAc, carboxy, -(CH₂)_pPO₃(R¹⁰)₂ or with the
 group
 -NR⁸R⁹,

R⁴ stands for hydrogen, halogen or C₁-C₄-alkyl,

R⁶, R⁷, R⁸,

R⁹, R¹⁰

and R¹¹, in each case independently of one another, stand for hydrogen or for


C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl,

m stands for 0 to 8, and

n and p stand for 0 to 6, or isomers, diastereomers, enantiomers or salts thereof.

2. (Cancelled)

3. (Currently Amended) Compounds of formula (I),



in which

A stands for phenylene or thiophenylene,

B stands for a bond or for C₁-C₁₂-alkylene, C₃-C₈-cycloalkylene or
 phenylene or thiophenylene that is optionally substituted in one or more places

in the same way or differently with hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl
or

-(CH₂)_pSO₃R⁸,

X and Y, in each case independently of one another, stand for oxygen or for the
group -NR¹¹-, -NR¹¹(CH₂)-, -CONR⁸-, -SO₂NR⁸- or -NR⁸CONR⁹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen,
halogen, nitro, C₁-C₆-alkyl, or for -NR⁸R⁹, -C₁-C₆-alkyloxy-C₁-C₆-alkyloxy or
-S(O)₂NR⁸R⁹,

R² stands for hydrogen,

R³ stands for hydrogen, halogen, cyano, C₁-C₁₀-alkyl or -CONR⁸R⁹,

R⁴ stands for hydrogen,

R⁸,

R⁹

and R¹¹, in each case independently of one another, stand for hydrogen or for
C₁-C₁₀-alkyl,

n stands for 0 to 6,

m stands for 0 to 4, and

p stands for 0 to 6,

or isomers, diastereomers, enantiomers or salts thereof.

4. (Previously Presented) Compounds of formula (I), according to claim 3,
in which

A stands for phenylene,

B stands for a bond or for C₁-C₁₂-alkylene, cyclohexylene or phenylene that
is optionally substituted in one or more places in the same way or differently
with hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl or
-(CH₂)SO₃R⁸,

X stands for oxygen or for the group -CONR⁸-, -SO₂NR⁸- or
-NR⁸CONR⁹-,

Y stands for oxygen or for the group -NR¹¹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen, amino,

halogen, nitro, C₁-C₆-alkyl, or for the group -NR⁸R⁹, -C₁-C₆-alkyloxy- C₁-C₆-alkyloxy or -S(O)₂NR⁸R⁹,

R² stands for hydrogen,

R³ stands for hydrogen, halogen, cyano, C₁-C₁₀-alkyl, or -CONR⁸R⁹,

R⁴ stands for hydrogen,

R⁸, R⁹ and R¹¹, in each case independently of one another, stand for hydrogen or for methyl or isobutyl,

m stands for 0 to 4, and

p stands for 0 to 6,

as well as isomers, diastereomers, enantiomers, and salts thereof.

5. (Previously Presented) Compounds of formula (I), according to claim 3,
in which

A stands for phenylene,

B stands for a bond or for C₁-C₁₂-alkylene that is optionally substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-hydroxyalkyl or -(CH₂)SO₃R⁸,

X stands for oxygen or for the group -SO₂NR⁸- or -NR⁸CONR⁹- ,

Y stands for the group -NR¹¹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen, amino, halogen, nitro or for the group -S(O)₂NR⁸R⁹,

R² stands for hydrogen,

R³ stands for halogen or cyano,

R⁴ stands for hydrogen,

R⁸, R⁹ and R¹¹ in each case stand for hydrogen, and

m stands for 0 to 4,

or isomers, diastereomers, enantiomers or salts thereof.


6. (Canceled)

7. (Cancelled)

8. (Cancelled)

9. (Previously Presented) Process for the production of the compounds of formula I according to claim 1, wherein either


a) compounds of formula VIII



(VIII)

in which R^1 , R^2 , R^3 , R^4 , R^5 , X , Y , A , B , m and n have the meanings that are indicated in formula I, and L stands for a leaving group, are cyclized with an acid to compounds of formula I, or

b) the acyclic precursors of formula (IX)



in which R^1 , R^3 , R^4 , R^5 , X , Y , A , B , m and n have the meanings that are indicated in formula I, and L stands for a leaving group, are first reduced to amine in a solvent and a reducing agent at 0°C until reflux takes place and then the intermediately formed amine is cyclized to the compounds of formula I.

10. (Canceled)

11. (Canceled)

12. (Currently Amended) A method for the treatment of hormone-independent human breast cancer, human nonsmall-cell lung cancer, human colon cancer, hormone-independent human prostate cancer, or hormone-independent, multiple pharmaceutical agent-resistant human breast cancer, as solid tumors, tumor or metastasis growth, Kaposi's sarcoma, Hodgkin's disease or leukemia, comprising administering to a host in need thereof a compound of formula I according to claim 1.

13. (Cancelled)

14. (Previously Presented) A pharmaceutical composition, comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

15. (Cancelled)

16. (Cancelled)

17. (Previously Presented) A pharmaceutical composition, comprising compound according to claim 3 and suitable formulation substances and vehicles.

18. (Cancelled)

19. (Cancelled)


20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Previously Presented) Compounds of formula I



in which

A stands for phenylene or thiophenylene,

B stands for C₁-C₁₂-alkylene, C₃-C₈-cycloalkylene, or phenylene that is optionally substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, or -(CH₂)_pSO₃R⁸,

X and Y, in each case independently of one another, stand for oxygen, sulfur or for the group -NR¹¹-, -NR¹¹(CH₂)-, -CONR⁸-, -SO₂NR⁸-, -S(O)₂N(COR⁸)-, -NR⁸SO₂-, or -NR⁸CONR⁹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen, halogen, nitro, C₁-C₆-alkyl or for the group -C₁-C₆-alkyloxy-C₁-C₆-alkyloxy, -NR⁸R⁹, -NR⁸COR⁹, -S(O)₂NR⁸R⁹, -S(O)₂N=CH-NR⁸R⁹, -CO₂H, -CO₂R⁸, -CONR⁸R⁹,

R² stands for hydrogen,

R³ stands for hydrogen, halogen, cyano, C₁-C₁₀-alkyl, -CONR⁸R⁹,

R⁴ stands for hydrogen,

R⁶, R⁷, R⁸,

R⁹, R¹⁰

and R¹¹, in each case independently of one another, stand for hydrogen or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, -N(C₁-C₆-alkyl)₂, or -SO(C₁-C₆-alkyl),

m stands for 0 to 8,

p stands for 0 to 6, and

n stands for 1

or diastereomers, enantiomers or salts thereof.